• Andrew N Claxton and Paul M Dark.
• Academic Clinical Fellow in Intensive Care Medicine, Nanomedicine Lab, Division of Pharmacy and Optometry, University of Manchester, Salford Royal NHS Foundation Trust, Salford M6 8HD.
• Brit J Hosp Med. 2018 Mar 2; 79 (3): 136-141.

AbstractSepsis is a medical emergency, which requires the initiation of broad-spectrum antimicrobial agents as early as possible. In the absence of positive microbiological cultures providing targeted antimicrobial advice, broad-spectrum antibiotics are commonly continued until there is clinical evidence of infection resolution. With an absence of robust evidence to inform when it is safe to stop antimicrobial agents in sepsis, the duration of antimicrobial courses may be longer than is required. Prolonged courses of potent broad-spectrum antimicrobials increase the risk of adverse drug events and contribute to the growing emergence of multidrug resistant pathogens, which is a global public health emergency. The protocolised use of protein biomarkers to guide clinical decision making can be used to help combat excessive durations of antimicrobials in patients with sepsis. This article reviews the current evidence for biomarker-guided antimicrobial discontinuation protocols in sepsis, identifies related evidence gaps and examines future innovation challenges in this field.

10 keywords...

hide…